Ashley Yeo
Executive Editor, MTI; Medtech Editor, In Vivo
Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest From Ashley Yeo
AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.
CMR Surgical Targeting New RAS Procedures And Markets For Growth
Marcio Coelho, chef commercial officer of robotic assisted surgery company CMR Surgical, updated In Vivo on the company’s unique approach to expanding uptake of its technologies in global markets, including those that are underserved in RAS devices.
AI In Cough Diagnosis: Making A Vicious Cycle Virtuous
Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.
UK Regulatory Update: MHRA Adds More Medtech UK Approved Body Capacity in August
The number of UK approved bodies designated to issue UKCA marking leapt from four to seven in August, adding much-needed file auditing capacity to Great Britain’s evolving medtech regulatory system. Next up: the MHRA’s consultation on accepting overseas-approved products onto the market.
Swissdamed Medtech Database Scheduled for January ‘Go-Live’
A pilot trial of the swissdamed database – an initiative designed to mirror the EU’s Eudamed – was successfully completed in June, allowing the regulator Swissmedic to confirm live implementation in January 2024. Work on two swissdamed modules is underway.